A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : DAT / dual antiplatelet therapy

[Related PubMed/MEDLINE]
Total Number of Papers: 68
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   DAT  (>> Co-occurring Abbreviation)
Long Form:   dual antiplatelet therapy
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Effects of Cilostazol-Based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy After Coronary Drug-Eluting Stent Implantation: An Updated Meta-Analysis of the Randomized Controlled Trials. CI, DES, MI, RCTs, RR, ST, TAT, TLR, TVR
2019 The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease. TAT, TEG, TIA
2018 Effect of dual antiplatelet on recurrent stroke in minor stroke or TIA depends on bodyweight. HR, MAT
2018 Feasibility of coronary fractional flow reserve with dual anti-platelet therapy in low risk coronary lesions without systemic anticoagulation-results of the SMART-FFR study. FFR, MACE
2018 Precision of VerifyNow P2Y12 Assessment of Clopidogrel Response in Patients Undergoing Cerebral Aneurysm Flow Diversion. PRU
2018 The efficacy and safety of cilostazol as an alternative to aspirin in Chinese patients with aspirin intolerance after coronary stent implantation: a combined clinical study and computational system pharmacology analysis. MACEs, PCI
2017 Single versus double antiplatelet therapy in patients undergoing coronary artery bypass grafting with coronary endarterectomy: mid-term results and clinical implications. CABG, CE
2017 The Effect of Cilostazol on the Angiographic Outcome of Drug-Eluting Coronary Stents Angiographic Analysis of the CILON-T (Influence of CILostazol-Based Triple Antiplatelet Therapy ON Ischemi Complication after Drug-Eluting StenT Implantation) Trial. DES, TAT, TLR
2017 [The new 2017 European society of cardiology (ESC) guidelines: important changes for introduction into clinical practice]. ESC, STEMI
10  2016 Perioperative management of patient with intracoronary stent presenting for noncardiac surgery. ICS, NCS, STh
11  2016 Risks and Benefits of Dual Antiplatelet Therapy Beyond 12 Months After Coronary Stenting: A Prospective Randomized Cohort Study. MACCE
12  2016 [Neurosurgery in a patient on dual antiplatelet therapy. Case report and the review of the literature]. ---
13  2015 Dual antiplatelet therapy increases pocket hematoma complications in Chinese patients with pacemaker implantation. ASA
14  2015 Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy after drug-eluting stent implantation in coronary arteries: A meta-analysis of randomized controlled trials. DES, LL, MACEs, RR, SMD, TAT, TLR, TVR
15  2015 Low-molecular-weight heparin or dual antiplatelet therapy is more effective than aspirin alone in preventing early neurological deterioration and improving the 6-month outcome in ischemic stroke patients. DVT, END, ERIS, LMWH
16  2015 Patterns of Antiplatelet Therapy in Patients Who Have Experienced an Acute Coronary Event: A Descriptive Study in UK Primary Care. AP, ASA, GI, PPIs
17  2015 Study design of the influence of SErotonin inhibition on patients with RENAl impairment or diabetes undergoing drug-eluting stent implantation (SERENADE) study: A multicenter, open-label, prospective, randomized study. CKD, DES, DM, TAT
18  2015 Use of thromboelastography to tailor dual-antiplatelet therapy in patients undergoing treatment of intracranial aneurysms with the Pipeline embolization device. PED, TEG, TIAs
19  2015 Ventriculoperitoneal shunt in a patient with ruptured blister aneurysm treated with pipeline embolization device. CSF, EVD, PED, VPS
20  2014 Cilostazol eliminates adverse smoking outcome in patients with drug-eluting stent implantation. DES, MACCE, PCI, TAT
21  2014 Increased risk for developing major adverse cardiovascular events in stented Chinese patients treated with dual antiplatelet therapy after concomitant use of the proton pump inhibitor. MACE, MI, PCI, PPI, ST
22  2014 Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons. ADP, MACE, MI, OR, PCI, RCTs, TLR, TVR
23  2014 Platelet inhibition by adjunctive cilostazol suppresses the frequency of cerebral ischemic lesions after carotid artery stenting in patients with carotid artery stenosis. CAS
24  2013 Antiplatelet theRapy after Genous EPC-capturing coroNary stenT implantatiOn: the ARGENTO study: a prospective, multicenter registry. GRS, MACEs, MI, PCI, ST, TVR
25  2013 Circulating endothelial progenitor cells are inversely correlated with in-stent restenosis in patients with non-ST-segment elevation acute coronary syndromes treated with EPC-capture stents (JACK-EPC trial). ACS, BMS, CTO, EPCs, LL, MACE, PCI, QCA
26  2013 Efficacy and safety of adjunctive cilostazol to dual antiplatelet therapy after stent implantation: an updated meta-analysis of randomized controlled trials. CIs, RCTs, RR
27  2013 Efficacy and safety of triple-antiplatelet therapy after percutaneous coronary intervention: a meta-analysis. CI, MACEs, MI, PCI, RCTs, RR, TLR, TVR
28  2013 Hematoma complicating permanent pacemaker implantation: the role of periprocedural antiplatelet or anticoagulant therapy. LMWH
29  2013 Long-term effect of dual antiplatelet treatment after off-pump coronary artery bypass grafting. ACS, OPCAB
30  2013 Major bleeding in patients undergoing PCI and triple or dual antithrombotic therapy: a parallel-cohort study. MACEs, TT
31  2013 Randomized comparison of new dual-antiplatelet therapy (aspirin, prasugrel) and triple-antiplatelet therapy (aspirin, clopidogrel, cilostazol) using P2Y12 point-of-care assay in patients with STEMI undergoing primary PCI. PCI, STEMI, TAT
32  2013 Risk of long-term dual antiplatelet therapy following drug-eluting stent implantation in octogenarians. BMSs, CI, DES
33  2013 Telephone contact to improve adherence to dual antiplatelet therapy after drug-eluting stent implantation. DES
34  2013 Triple versus dual antiplatelet therapy for coronary heart disease patients undergoing percutaneous coronary intervention: A meta-analysis. CHD, CI, MACE, OR, PCI, TAT, TLR
35  2013 Use of clopidogrel and proton pump inhibitors after a serious acute coronary event: risk of coronary events and peptic ulcer bleeding. PPIs, PUB, RR
36  2012 Beneficial impact of prolonged dual antiplatelet therapy after drug-eluting stent implantation. DES, MACCE
37  2012 Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients. MACEs, RCTs, TAT
38  2012 Double antiplatelet therapy after drug-eluting stent implantation: risk associated with discontinuation within the first year. ATD, CI, DES
39  2012 Dual antiplatelet therapy after myocardial infarction and percutaneous coronary intervention: analysis of patient adherence using a French health insurance reimbursement database. MI, PCI
40  2012 Dual antiplatelet therapy in peripheral arterial disease and after peripheral percutaneous revascularization. PAD, SFA
41  2012 Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and in combination in a porcine model of stent thrombosis. ASA, i.v
42  2012 Genetic determinations of variable responsiveness to clopidogrel and implications for neurointerventional procedures. PCI
43  2012 Impact of dual antiplatelet therapy with proton pump inhibitors on the outcome of patients with acute coronary syndrome undergoing drug-eluting stent implantation. PCI, PPIs, re-ACS, TVR
44  2012 OPTIMA Tacrolimus-eluting Stent: A Twelve-month Clinical Follow up with Two Different Periods of Dual Antiplatelet Therapy; 2-month vs. 6-month Approach. MACE, TES, TLR
45  2012 Reduced antiplatelet therapy after drug-eluting stenting: multicenter Janus Flex carbostent implantation with short dual antiplatelet treatment for 2 or 6 months-MATRIX study. MACE, MI, ST, TLR
46  2012 Use of cilostazol in percutaneous coronary interventions. MACEs, PCI
47  2012 What do you do with the antiplatelet agents in patients with drug eluting stents who then receive a mechanical valve? DES, OAC, TT
48  2011 Adequate antiplatelet regimen in patients on chronic anti-vitamin K treatment undergoing percutaneous coronary intervention. AVK, MACE, PCI
49  2011 Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy. AU min, CHD
50  2011 Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. CI, CILON-T, DES, HR, TAT, TLR
51  2011 Percutaneous coronary interventions with an endothelial progenitor cell capture stent (EPC) for high risk patients with no option for drug eluting stents: long term clinical outcomes of a single centre registry. DES, EPC, EPC, MACE, TLR, TVR
52  2011 Post percutaneous coronary intervention antiplatelet therapy: current perceptions, prospects and perplexity. BMS, DES, PCI
53  2011 Rationale and results of percutaneous coronary revascularization with endothelial progenitor cell capture stent in high-risk patients requiring undeferrable non-cardiac surgery. DES, EPC, MACE, MI, ST, TVR
54  2011 Repetitive early stent thrombosis in a patient with the CYP2C19*3/*3 genotype. CAG, RCA
55  2011 The potential benefits and risks of the use of dual antiplatelet therapy beyond 6 months following sirolimus-eluting stent implantation for low-risk patients. MI
56  2010 Bleeding complications after pacemaker or cardioverter-defibrillator implantation in patients receiving dual antiplatelet therapy: Results of a prospective, two-centre registry. ASA
57  2010 National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin. AE, CI, ED
58  2010 Prolonged double antiplatelet therapy in a cohort of "de novo" diabetic patients treated with drug-eluting stent implantation. DM
59  2010 Proton pump inhibitors and clopidogrel: is it a significant drug interaction? GI, PPI
60  2010 Real-world outcome of coronary bifurcation lesions in the drug-eluting stent era: results from the 4,314-patient Italian Society of Invasive Cardiology (SICI-GISE) Italian Multicenter Registry on Bifurcations (I-BIGIS). DESs, I-BIGIS, MACEs, SICI-GISE
61  2010 Stent thrombosis and duration of dual antiplatelet therapy. BMS, DES, ST
62  2010 The H(2)-receptor antagonist ranitidine interferes with clopidogrel-mediated P2Y(12) inhibition in platelets. PPIs, PRI
63  2010 [Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation: a retrospective cohort study]. GI, MACE, PPIs
64  2009 Antiplatelet therapy discontinuation following drug-eluting stent placement: dangers, reasons, and management recommendations. BMS, DES, ST
65  2009 Incidence of stent thrombosis in patients with drug eluting stents and short-term dual antiplatelet therapy. DES, PES, SES, ST
66  2009 Stent choice in primary percutaneous coronary intervention: drug-eluting stents or bare metal stents? DES, PCI, STEMI, TVR
67  2009 Therapeutic strategies after coronary stenting in chronically anticoagulated patients: the MUSICA study. AC, OAT, PCI-S, TT
68  2008 Incidence of bleeding and compliance on prolonged dual antiplatelet therapy (aspirin + thienopyridine) following drug-eluting stent implantation. CI, DES